Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03688152
Recruitment Status : Recruiting
First Posted : September 28, 2018
Last Update Posted : June 28, 2019
Sponsor:
Information provided by (Responsible Party):
Incyte Corporation

Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Condition or disease Intervention/treatment Phase
Relapsed Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma Drug: INCB053914 Drug: INCB050465 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Actual Study Start Date : December 3, 2018
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : September 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: INCB053914 + INCB050465
INCB053914 in combination with INCB050465.
Drug: INCB053914

Dose Escalation: INCB053914 at the protocol-defined starting dose in combination with INCB050465, with dose modifications based on tolerability criteria.

Dose Expansion: Recommended dose from the dose-escalation study.


Drug: INCB050465

Dose Escalation: INCB050465 at the protocol-defined starting dose in combination with INCB053914, with dose modifications based on tolerability criteria.

Dose Expansion: Recommended dose from the dose-escalation study.





Primary Outcome Measures :
  1. Number of treatment-emergent adverse events (TEAEs) [ Time Frame: Up to approximately 6 months ]
    TEAE is defined as an adverse event reported for the first time or worsening of a pre-existing event after the first dose of study treatment.


Secondary Outcome Measures :
  1. Cmax of INCB053914 in combination with INCB050465 [ Time Frame: Day 15 ]
    Maximum observed plasma concentration.

  2. Tmax of INCB053914 in combination with INCB050465 [ Time Frame: Day 15 ]
    Time to maximum plasma concentration.

  3. Cmin of INCB053914 in combination with INCB050465 [ Time Frame: Day 15 ]
    Minimum observed plasma concentration during the dosing interval.

  4. AUC0-t of INCB053914 in combination with INCB050465 [ Time Frame: Day 15 ]
    Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration.

  5. Cl/F of INCB053914 in combination with INCB050465 [ Time Frame: Day 15 ]
    Oral dose clearance.

  6. Overall response rate [ Time Frame: Up to approximately 6 months ]
    Defined as the percentage of participants with a complete remission (CR)/complete metabolic response (CMR) or partial remission (PR)/partial metabolic response (PMR) as defined by investigator assessment per revised Lugano classification criteria for lymphomas.

  7. Duration of response [ Time Frame: Up to approximately 6 months ]
    Defined as the time from first documented evidence of CR/CMR or PR/PMR until disease progression or death from any cause among participants who achieve an objective response, as determined by radiographic disease assessment.

  8. Progression-free survival [ Time Frame: Up to approximately 6 months ]
    Defined as the time from the date of the first dose of any study drug until the earliest date of disease progression, as determined by radiographic disease assessment, or death from any cause, whichever occurs first.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Relapsed or refractory DLBCL, which has been histologically documented, defined as having received at least 2 but no more than 5 prior systemic treatment regimens (eg, an anti-CD20 antibody, an anti-CD20 antibody with or without chemotherapy, or chemotherapy alone) and ineligible for further treatment with standard of care.
  • Willing to undergo pretreatment and on-treatment incisional or excisional biopsy of nontarget adenopathy or extranodal lesions. Provision of the most recent, available archived tumor biopsy may satisfy the pretreatment biopsy.
  • Measurable disease as defined by the Lugano classification criteria:

    • ≥ 1 measurable nodal lesion (≥ 1.5 cm in longest dimension) or ≥ 1 measurable extranodal lesion (> 1 cm in longest dimension) on CT scan or MRI
    • ≥ 1 PET-avid lesion.
  • Eastern Cooperative Oncology Group performance status 0 to 2.
  • Willingness to avoid pregnancy or fathering children based on protocol-defined the criteria.

Exclusion Criteria:

  • Laboratory values outside the protocol-defined range at screening unless approved by the medical monitor.
  • Primary mediastinal (thymic) large B-cell lymphoma or Richter's Syndrome.
  • Known brain or central nervous system metastases or history of uncontrolled seizures.
  • Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment.
  • Allogeneic stem cell transplant within the last 6 months, or active graft-versus-host disease following allogeneic transplant, or autologous stem cell transplant within the last 3 months before the date of the first dose of study treatment.
  • Use of immunosuppressive therapy following allogenic transplant within 28 days of the first dose of study treatment.
  • Prior treatment with a PIM inhibitor, selective PI3Kδ inhibitor (eg, idelalisib), or a pan-PI3K inhibitor.
  • Receipt of anticancer medications, therapies, or investigational drugs within protocol-defined intervals before the date of the first dose of study treatment.
  • Current or previous other malignancy within 3 years of study entry, except cured (or treated with curative intent and no evidence of disease) basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy without sponsor approval.
  • History of liver function abnormality requiring investigation and/or treatment (eg, due to excessive alcohol or drug-induced liver injury).
  • Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric disease.
  • Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment, and exposure to a live vaccine within 30 days of study treatment administration.
  • Known HIV infection.
  • Evidence of HBV or HCV infection.
  • History of stroke or intracranial hemorrhage within 6 months of the date of study treatment administration.
  • History of clinically significant or uncontrolled cardiac disease.
  • Presence of an abnormal ECG that is clinically meaningful. Screening QTc interval > 480 milliseconds is excluded (corrected by Fridericia).
  • Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03688152


Contacts
Layout table for location contacts
Contact: Incyte Corporation Call Center (US) 1.855.463.3463 medinfo@incyte.com

Locations
Layout table for location information
United States, Arizona
University of Arizona Cancer Center Recruiting
Tucson, Arizona, United States, 85719
Principal Investigator: Dr. Daniel Persky         
United States, California
UCLA Healthcare Hematology-Oncology Recruiting
Santa Monica, California, United States, 90404
Principal Investigator: Dr. Sven DeVos         
United States, New York
Clinical Research Alliance Recruiting
Lake Success, New York, United States, 11042
Principal Investigator: Dr. Morton Coleman         
Sponsors and Collaborators
Incyte Corporation
Investigators
Layout table for investigator information
Study Director: Fred Zheng, MD Incyte Corporation

Layout table for additonal information
Responsible Party: Incyte Corporation
ClinicalTrials.gov Identifier: NCT03688152     History of Changes
Other Study ID Numbers: INCB 53914-102
First Posted: September 28, 2018    Key Record Dates
Last Update Posted: June 28, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Incyte Corporation:
Diffuse large B-cell lymphoma
DLBCL
Non-Hodgkin lymphoma
phosphatidylinositol 3-kinase delta inhibitor
PI3Kδ
PIM kinases
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin